Stay updated on Pembrolizumab Combo in Resectable NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The page's revision tag was updated to v3.5.4 and the previous v3.5.3 tag was removed, signaling a small update to the page’s revision history.
    Difference
    0.0%
    Check dated 2026-05-14T23:19:03.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Taoyuan District, Taiwan, 333 was removed and Taoyuan, Taiwan, 333 was added to the study locations in Taiwan. This updates the geographic coverage and enrollment options for participants in that region.
    Difference
    0.0%
    Check dated 2026-05-07T21:50:34.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The page now displays revision v3.5.3, replacing the previous v3.5.2. This reflects a version update rather than a change to trial content.
    Difference
    0.0%
    Check dated 2026-04-30T15:37:52.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    City location text for Bucharest, Romania changed from the Romanian spelling (“București”) to the English spelling (“Bucharest”) while keeping the same address entry.
    Difference
    0.0%
    Check dated 2026-04-23T13:59:05.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    Revision label updated from v3.5.0 to v3.5.2. No study content or features were changed.
    Difference
    0.0%
    Check dated 2026-04-16T09:55:30.000Z thumbnail image
  7. Check
    55 days ago
    Change Detected
    Summary
    Publication added under Publications: A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II NSCLC from KEYNOTE-671. Eur J Cardiothorac Surg. 2026 Mar 10; 68(3): ezag028.
    Difference
    0.0%
    Check dated 2026-04-02T00:13:38.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Resectable NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.